AKT1 and neutropenia: It has been reported that patients could tolerate the combination of AKT inhibitors and chemotherapeutic agents, however, they suffer from serious toxic side effects such as diarrhea, infection, neutropenia, rash, and fatigue, which might be attributed to their suboptimal pharmacokinetics and poor biodistribution in the body.[14] Hence, effective means of delivering both AKT inhibitors and chemotherapeutic agents to achieve potent combinatorial therapeutic effects and reduce their side effects have been pursued.